HOME >> MEDICINE >> NEWS
New data at ASCO show CAMPTOSAR is key to treating 1st line metastatic colorectal cancer

aluated the impact of adding bevacizumab to FOLFIRI and mIFL. A statistically significant improvement in OS for patients treated with FOLFIRI plus bevacizumab was seen when compared with those receiving mIFL plus bevacizumab. A total of 87 percent of patients were still alive after one year compared to 61 percent of patients given mIFL plus bevacizumab. The most frequent grade 3/4 adverse events in both arms were diarrhea, neutropenia and hypertension, with neutropenia and hypertension being higher in the FOLFIRI plus bevacizumab arm.

"This study enhances our understanding of combining FOLFIRI with the targeted agent bevacizumab as a standard treatment in first-line metastatic colorectal cancer patients," said Dr. Fuchs. "FOLFIRI plus bevacizumab significantly improved OS when compared to mIFL plus bevacizumab and both regimens were tolerable."


'"/>

Contact: Rachel Leopold
rachel.leopold@edelman.com
212-704-4433
Edelman Public Relations
5-Jun-2006


Page: 1 2

Related medicine news :

1. Study shows radiofrequency ablation highly effective in treating kidney tumors
2. Tumor cell activity may provide clues for treating breast cancer in young women
3. Mouse model points to possible new strategy for treating rare muscle disease, kidney disorders
4. Help for pediatricians in treating behavioral health problems only partially successful
5. ECP may be effective in treating Crohns disease
6. New guideline for treating Lyme disease
7. Certain combination therapy found more effective for treating malaria in African children
8. Article outlines current recommendations for treating malaria in the US
9. One pill may be better than two for treating patients with high blood pressure
10. Effectiveness of first renin inhibitor drug for treating hypertension is limited
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Post Your Comments:
(Date:5/26/2015)... CA (PRWEB) May 27, 2015 ... beautiful technology for women, today announces the ... monitors women’s stress, sleep, activity and ovulation. The ... with innovative health tracking technolo- gy, particularly its ... levels, to provide women with lifestyle data and ...
(Date:5/26/2015)... May 27, 2015 Securityhunter ... (MATOC) by the United States Department of Health and ... The MATOC was awarded through the General ... (FSS) for the PSC, which is a fee-for-service agency. ... one year options, and is an enterprise–wide physical security ...
(Date:5/26/2015)... (PRWEB) May 27, 2015 This summer, ... connecting with local communities at key events in Greater Boston ... supplied with free copies of ChopChop Magazine, healthy snacks and ... to stay active. , “We want to get our message ... out in a memorable and fun way,” explains Sally Sampson, ...
(Date:5/26/2015)... 26, 2015 Mr. Gould and Mr. Ken ... start working together this week to ensure a smooth transition. ... healthcare executive leadership and strategy. Gary is familiar with ... hiring of Mr. Cochran. The Board of Trustees believe Mr. ... improvement strategies implemented over the past few years. , ...
(Date:5/26/2015)... May 26, 2015 The federal court ... filed on behalf of individuals who were allegedly injured ... June 11th Science Day. According to an Order issued ... on May 21st, topics to be addressed include Xarelto ... use of blood test based testing with Xarelto, and ...
Breaking Medicine News(10 mins):Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 3Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Award-Winning Cooking Magazine for Kids Takes Healthy Cooking and Eating to the Streets with One-of-a-Kind Bike Campaign 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 3Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 4
(Date:5/26/2015)... -- OrthoAccel ® Technologies, Inc., the leader in non-invasive, accelerated ... response to continued demand from orthodontists and patients for ... practice locations in the U.S. and Canada ... is the only FDA-cleared Class II medical device that ... as much as 50 percent.  A ...
(Date:5/26/2015)... 2015 Aethlon Medical, Inc. (OTCQB: AEMD), ... address infectious diseases and cancer, today announced that ... will present at the SeeThruEquity 4th Annual Microcap ... Aethlon Medical,s presentation are as follows:Event: , SeeThruEquity ... May 28, 2015Time: , 8:00 a.m. Pacific Time ...
(Date:5/26/2015)... -- ViiV Healthcare, Aurobindo Pharma, and the ... Aurobindo Pharma has submitted an Abbreviated New Drug Application ... Food and Drug Administration (FDA), for the treatment of ... version of dolutegravir, less than two years after FDA ... the United States . Upon receiving ...
Breaking Medicine Technology:OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 3Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 2Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 3Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 3ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 5ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 6ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 7
Cached News: